1-20 of 83
Adam D. Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
DOI: https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

Adam D Cohen, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Oksana De Mesa, Elizabeth Kane, Charles Nichols, Beatrice Razzo, Edward A. Stadtmauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 12628–12629.
DOI: https://doi.org/10.1182/blood-2022-165526
Published: 2022
Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 4349–4351.
DOI: https://doi.org/10.1182/blood-2022-166609
Published: 2022
Journal Articles

Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Brian Hoeynck, Wei-Ting Hwang, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya, Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Adam D Cohen
Journal: Blood
Blood (2022) 140 (Supplement 1): 10081–10083.
DOI: https://doi.org/10.1182/blood-2022-165650
Published: 2022
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
DOI: https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ Van De Donk, Mounzer Agha, Adam D Cohen, Yael C Cohen, Sébastien Anguille, Tessa Kerre, Wilfried W.H. Roeloffzen, Jordan M Schecter, Kevin C De Braganca, Carolyn C Jackson, Helen Varsos, Pankaj Mistry, Tito Roccia, Xiaoying Xu, Katherine Li, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7536–7537.
DOI: https://doi.org/10.1182/blood-2022-159169
Published: 2022
Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez Otero, Bruno Paiva, Niels W.C.J. Van De Donk, Thomas Martin, Attaya Suvannasankha, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Helen Varsos, William Deraedt, Tito Roccia, Pankaj Mistry, Xiaoying Xu, Katherine Li, Enrique Zudaire, Muhammad Akram, Lida Pacaud, Irit Avivi, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4646–4648.
DOI: https://doi.org/10.1182/blood-2022-158563
Published: 2022
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
DOI: https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D Cohen, Amrita Y. Krishnan, Rafael Fonseca, Andrew Spencer, Jesús G. Berdeja, Alexander Lesokhin, Peter A Forsberg, Jacob P. Laubach, Luciano J. Costa, Paula Rodriguez-Otero, Rayan Kaedbey, Joshua Richter, Maria-Victoria Mateos, Sheeba K Thomas, Chihunt Wong, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 157.
DOI: https://doi.org/10.1182/blood-2021-147983
Published: 2021
Journal Articles

Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity

Wesley Wilson, Fei Miao, Alfred L Garfall, Dexiu Bu, Elena J Orlando, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Adam D Cohen, Michael C. Milone
Journal: Blood
Blood (2021) 138 (Supplement 1): 1707.
DOI: https://doi.org/10.1182/blood-2021-151785
Published: 2021
Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Rakesh Popat, Ashraf Z. Badros, Shaji Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2746.
DOI: https://doi.org/10.1182/blood-2021-152681
Published: 2021
Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Niels W.C.J. Van de Donk, Michel Delforge, Mounzer Agha, Adam D Cohen, Yael C Cohen, Jens Hillengass, Sebastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Tonia Nesheiwat, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2910.
DOI: https://doi.org/10.1182/blood-2021-146074
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
DOI: https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Caitlin Costello, Ben A Derman, Mehmet Hakan Kocoglu, Abhinav Deol, Abbas Abbas Ali, Tara Gregory, Bhagirathbhai Dholaria, Jesus G Berdeja, Adam D Cohen, Krina K. Patel, David S. Siegel, Rajneesh Nath, Katherine McArthur, Joanne McCaigue, Christopher E Martin, Majid Ghoddusi, Hamid Namini, Eric M. Ostertag, Matthew A. Spear, Rajesh Belani, Nina Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 3858.
DOI: https://doi.org/10.1182/blood-2021-151672
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yael C. Cohen, Adam D Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu-min Yeh, Liwei Wang, Martin Vogel, Christina Corsale, Muhammad Akram, Lida Pacaud, Tonia Nesheiwat, Mounzer Agha, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 3866.
DOI: https://doi.org/10.1182/blood-2021-146072
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Andrzej Jakubowiak, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, Jordan M. Schecter, Deepu Madduri, Tzu-Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia Allred, Enrique Zudaire, William Deraedt, Changwei Zhou, Dong Geng, Lida Pacaud, Yi Lin, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3938.
DOI: https://doi.org/10.1182/blood-2021-146069
Published: 2021
Journal Articles

Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma

Sundar Jagannath, Nedra Joseph, Concetta Crivera, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Xueting Yu, Lee Smolen, Adam D Cohen
Journal: Blood
Blood (2021) 138 (Supplement 1): 4964.
DOI: https://doi.org/10.1182/blood-2021-153438
Published: 2021
Journal Articles

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Parameswaran Hari, MD MRCP, Myo Htut, MD, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, William Deraedt, MSc, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Sigrid Crawford, MA, Ross Morrison, MPH, Lynda Doward, MRes, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–15.
DOI: https://doi.org/10.1182/blood-2020-136383
Published: 2020
Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
DOI: https://doi.org/10.1182/blood-2020-142695
Published: 2020
Journal Articles

Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Thomas Martin, III, MD, Yi Lin, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, Myo Htut, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
DOI: https://doi.org/10.1182/blood-2020-136368
Published: 2020